Treat ctDNA

Evaluate whether elacestrant can delay the appearance of metastases to;distance or death compared to standard endocrine therapy;in patients with ER+/HER2- breast cancer with;relapse according to ctDNA;Secondary objectives;À Evaluate invasive disease-free survival (IDFS), survival without;relapse (RFS) and overall survival (OS) between the 2 groups of;treatment;À Characterize the safety and tolerance of the two groups of;treatment;À Establish the safety profile reported by the patient in each;treatment group;À Compare the benefit reported by the patient between the two groups;treatment